Protocol CAUSE-03 / CHEETAH (NCT06136091)
Mechanisms Underlying Asthma Symptoms and Exacerbations Examined Across T2 Status in Children (CHEETAH) (CAUSE-03)
🩺 Plain-English Summary (8th-Grade Level)
This is a one-year longitudinal, observational study of 250 urban children and adolescents with asthma and 60 without asthma, ages 6-17 years old. Participants with asthma will require daily controller therapy with inhaled corticosteroids ICS (at least Step 2 therapy). Those without asthma cannot have used asthma medications in the year prior to enrollment and cannot demonstrate bronchodilator reversibility at baseline. Phenotypic characteristics will be established at baseline, and the participants will be seen at scheduled visits over 12 months. Each participant will be asked to monitor and self-report cold symptoms and will be asked to complete up to three cold visits
Who can join: Review the eligibility criteria below.
Location: Children's Hospital Colorado: Allergy Program — Aurora, Colorado
Age range: 6 Years to 17 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Children's Hospital Colorado: Allergy Program — Aurora, Colorado
- Children's National Medical Center: Children's Research Institute — Washington D.C., District of Columbia
- Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology — Chicago, Illinois
- Boston University School of Medicine: Pulmonary Center — Boston, Massachusetts
- Boston Children's Hospital: Department of Immunology — Boston, Massachusetts
- Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute — New York, New York
- Columbia University Medical Center: Division of Pediatric Pulmonology — New York, New York
- Cincinnati Children's Hospital Medical Center: Asthma Center — Cincinnati, Ohio
📞 Contact the Study Coordinator
Phone: (720) 777-8384
Email: juana.cerna@childrenscolorado.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype — Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma — San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study — La Jolla, California
Explore by condition: All Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.